BioSoftware Progress

PharmScan 95
Mutamatic 75
Phimdit 60
Chimera Builder 40

Horizontal Tabs

Platform for the development of three-dimensional models and mass transport proteins sweep small molecule libraries (from ~ 300.000 to 11,000,000), to search, identification and classification of new rational drug transporter proteins with activity in humans. The formalization will be done through a web-accessible platform called PharmScan Transporter: Platform for conducting mass and molecular docking analysis applied to carrier proteins. Our proposal includes a series of applications developed during the course of doctoral thesis for the development of robust and automated three-dimensional models, where the two models generated 3D models are validated and used by the scientific community for glucose transporters and vitamin C. This gives us a competitive advantage that allows us to identify and commercially available groups of molecules with a high potential to interact with transporter targets, application should be in diabetes and cancer therapies, or other conditions depending on the selected membrane protein. Our proposal affects the efficiency of identification and selection of new drugs and therefore the decrease in production time and costs, which will have a direct impact on the final market prices, increasing the level of accessibility of these products by users on the same high impact diseases.
The medium-term objective is to package the new platform for rational design applied to carrier proteins and generate a portfolio of drug transporters, license applications developed and offer the following products: Three-dimensional model of the transporter of interest, listing identified small molecules, acquisition of small molecules to be tested, and clustered chemometric classification as substrates, activators or inhibitors, and finally development of new pharmacophores.
Mutamatic is a suite of programs written in python that allows automated design and stage of DNA primers to run experiments of site-directed mutagenesis.
a) Optimization of laboratory work. Laboratory work has migrated to the massive performing site-directed mutagenesis experiments, we have developed a method that optimizes the design process by automating the steps with consequent gains time and minimizes errors. We design 100 starters in 1 minute, where time is normally 30 minutes. Furthermore, the design allows the evaluation of the results without having to wait up to two weeks for sequencing results, allowing one day see if the experiment was positive.
b) own tool with the ability of extended functions. Creating this prototype allows us to develop a marketable product and transferring our technology product either through a software or a design on our servers. At the same time this basis would allow us to develop other extended design capabilities as alanine scans, mutagenic cassette design and protease cleavage sites.
It has developed an online platform for designing nucleotide primers for site directed mutations incorporating enzyme cleavage sites. Development chain reactions (PCR) multiple, and design of primers for PCR experiments in real time. Design of primers for identification of tissues and cell lines.
Platform supply and drug search. On this platform we call Phind-IT (pronounce find it!) Which is a web platform where pharmacies can create a personalized account and upload your weekly three steps stock with geo-reference your local. This platform is accompanied by a mobile application that allows users to examine in real time the database and verify the information provided by the pharmacy. We have also implemented an algorithm proposed other medication options based on geo-referenced availability and characteristics of the active ingredient in generic and bioequivalent. This new bussiness is financed by PRAE 35128 from CORFO, Chile.
Bioinformatics platform for the design and evaluation of chimeric proteins. The chimeric proteins are proteins designed by man, by merging existing proteins, which give a particular chimeric protein of interest and activity, generally for therapeutic use. Today, the pharmaceutical industry has produced biological drugs that are more likely to market that small synthetic molecules. Current biopharmaceuticals as chimeric proteins are antibodies, receptors or signaling molecules. These proteins are fused to other proteins which give new biophysical and pharmacological properties, such as increased half-life, stimulation of signaling pathways, stimulating the immune system, among others. These chimeric proteins are involved in current therapies high impact on the health of the population and its subsequent commercial success. Its applications are in diseases such as rheumatoid arthritis, various cancers and also in vaccines. ChimeraBuild is capable of generating chimeric proteins designs involving molecular structural and dynamic information in an automated manner. Moreover, its intuitive platform allows users not specialized in the construction of chimeras may use it, and also proposes new strategies based on the experience of 10 years of research. The comprehensive assessment of ChimeraBuild allows the user characterize prior to in vitro testing its chimeric protein, decreasing experimental costs.

Project Support